Invention Grant
US09109011B2 Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
有权
树突状细胞特异性抗体缀合物，其包含缀合HIV-1Gag / Nef的抗-CD40单克隆抗体
- Patent Title: Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
- Patent Title (中): 树突状细胞特异性抗体缀合物，其包含缀合HIV-1Gag / Nef的抗-CD40单克隆抗体
-
Application No.: US12504463Application Date: 2009-07-16
-
Publication No.: US09109011B2Publication Date: 2015-08-18
- Inventor: Jacques F. Banchereau , Gerard Zurawski , Anne-Laure Flamar , Amanda Cobb , Holly Mead , Monica Montes , Sandra Zurawski , SangKon Oh
- Applicant: Jacques F. Banchereau , Gerard Zurawski , Anne-Laure Flamar , Amanda Cobb , Holly Mead , Monica Montes , Sandra Zurawski , SangKon Oh
- Applicant Address: US TX Dallas
- Assignee: Baylor Research Institute
- Current Assignee: Baylor Research Institute
- Current Assignee Address: US TX Dallas
- Agency: Norton Rose Fulbright US LLP
- Main IPC: C07K14/005
- IPC: C07K14/005 ; C07K14/15 ; C07K16/28 ; A61K47/48 ; A61K39/21
Abstract:
The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
Public/Granted literature
- US20100135994A1 HIV VACCINE BASED ON TARGETING MAXIMIZED GAG AND NEF TO DENDRITIC CELLS Public/Granted day:2010-06-03
Information query
